Data from multiple previous studies on g-NEC have shown the following: 14 cases (with 64.3% TP53 genetic variation and 21.4% RB1 genetic variation, including copy number variations), 8 cases of gastric NEC (87.5% TP53 genetic alteration and 12.5% RB1 genetic alteration) (12), and 25 cases of gastric NEC, in which the rates of aberrant TP53 and RB1 genetic alterations were 68% and 36%, respectively (13). The gene discussed is TP53; the disease is neuroendocrine carcinoma.